Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
复制标题

DOI:
10.1007/s12672-015-0232-3
复制
发表时间:
2015-12
期刊:
影响因子:
3
通讯作者:
Richer JK
Richer JK
中科院分区:
医学2区
文献类型:
--
作者:
Barton VN;D'Amato NC;Gordon MA;Christenson JL;Elias A;Richer JK

文献摘要

参考文献

被引文献

相似文献

三阴性乳腺癌(TNBC)是一种侵袭性乳腺癌亚型,缺乏雌激素受体、孕激素受体和人表皮生长因子受体2(HER2)扩增。由于缺乏这些受体,TNBC对改善其他乳腺癌亚型患者预后的传统内分泌或HER2靶向治疗没有反应。TNBC预后不良,目前尚无有效的靶向治疗方法。一些TNBC肿瘤表达雄激素受体(AR),可能受益于AR靶向治疗。在这里,我们回顾了关于TNBC中AR的文献,并建议将TNBC进一步细分为AR+ TNBC或四阴性乳腺癌,因为靶向AR可能代表TNBC子集的可行治疗选择。
Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) amplification. Due to the absence of these receptors, TNBC does not respond to traditional endocrine or HER2-targeted therapies that improve patient prognosis in other breast cancer subtypes. TNBC has a poor prognosis, and currently, there are no effective targeted therapies. Some TNBC tumors express androgen receptor (AR) and may benefit from AR-targeted therapies. Here, we review the literature on AR in TNBC and propose that TNBC be further sub-classified as either AR+ TNBC or quadruple negative breast cancer since targeting AR may represent a viable therapeutic option for a subset of TNBC.
DOI: 10.1038/onc.2011.301
发表时间: 2012-03-01
期刊: ONCOGENE
影响因子: 8
作者:
Guedj, M.;Marisa, L.;de Reynies, A.;Orsetti, B.;Schiappa, R.;Bibeau, F.;MacGrogan, G.;Lerebours, F.;Finetti, P.;Longy, M.;Bertheau, P.;Bertrand, F.;Bonnet, F.;Martin, A. L.;Feugeas, J. P.;Bieche, I.;Lehmann-Che, J.;Lidereau, R.;Birnbaum, D.;Bertucci, F.;de The, H.;Theillet, C.
通讯作者: Theillet, C.
DOI: 10.1186/bcr3112
发表时间: 2012-02-09
期刊: Breast cancer research : BCR
影响因子: --
作者:
Garay JP;Karakas B;Abukhdeir AM;Cosgrove DP;Gustin JP;Higgins MJ;Konishi H;Konishi Y;Lauring J;Mohseni M;Wang GM;Jelovac D;Weeraratna A;Sherman Baust CA;Morin PJ;Toubaji A;Meeker A;De Marzo AM;Lewis G;Subhawong A;Argani P;Park BH
通讯作者: Park BH
DOI: 10.1111/j.1432-1033.2004.04395.x
发表时间: 2005-01-01
期刊: FEBS JOURNAL
影响因子: 5.4
作者:
Ahrens-Fath, I;Politz, O;Haendler, B
通讯作者: Haendler, B
DOI: 10.1038/sj.onc.1208561
发表时间: 2005-07-01
期刊: ONCOGENE
影响因子: 8
作者:
Farmer, P;Bonnefoi, H;Iggo, R
通讯作者: Iggo, R
DOI: 10.1016/j.humpath.2011.08.007
发表时间: 2012-07
期刊: Human pathology
影响因子: 3.3
作者:
Cimino-Mathews A;Hicks JL;Illei PB;Halushka MK;Fetting JH;De Marzo AM;Park BH;Argani P
通讯作者: Argani P